1. Volume 150, Issue 1, Pages 134-144.e10 (January 2016)
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B 
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, Florin A. Caruntu, Won Young Tak, Magdy Elkashab, Wan-Long Chuang, Seng-Gee Lim, Fehmi Tabak, Rajiv Mehta, Joerg Petersen, Graham R. Foster, Lillian Lou, Eduardo B. Martins, Phillip Dinh, Lanjia Lin, Amoreena Corsa, Prista Charuworn, G. Mani Subramanian, Hans Reiser, Hendrick W. Reesink, Scott Fung, Simone I. Strasser, Huy Trinh, Maria Buti, Giovanni B. Gaeta, Aric J. Hui, George Papatheodoridis, Robert Flisiak, Henry L.Y. Chan 
Gastroenterology 
Volume 150, Issue 1, Pages e10 (January 2016)
DOI: /j.gastro
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
Effect of TDF and peginterferon as combination or monotherapy on HBsAg loss. The rate of HBsAg loss in group A was significantly higher than rates for groups C (P < .001) or D (P=.003), as well as group B (unadjusted P < .001). The rate of HBsAg loss in group B did not significantly differ from that of groups C (P = .466) or group D (P = .883).
Gastroenterology  , e10DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
On-treatment HBsAg decline from baseline to week 48. Data shown are mean ± 95% CIs. Group A vs group B, P < .001; group A vs group C, P < .001; group A vs D, P = .016.
Gastroenterology  , e10DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

4. Supplementary Figure 1
Patient disposition. ∗Eleven subjects were randomized but not dosed; 4 withdrew consent after randomization and reasons are not provided for the remaining 7. †The analyzed population represents patients included in the Kaplan−Meier estimate, the missing = failure analysis and the safety analysis.
Gastroenterology  , e10DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions